{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:02:33Z","timestamp":1782309753823,"version":"3.54.5"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA030115"],"award-info":[{"award-number":["AA030115"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA029971"],"award-info":[{"award-number":["AA029971"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA031124"],"award-info":[{"award-number":["AA031124"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001391","name":"Whitehall Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA056196"],"award-info":[{"award-number":["DA056196"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA051136"],"award-info":[{"award-number":["DA051136"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH064913"],"award-info":[{"award-number":["MH064913"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The relative efficacies of nalmefene versus naltrexone for alcohol use disorder is the subject of intense and ongoing debate. The two pan-opioid receptor ligands differ primarily in actions at the kappa opioid receptor, where naltrexone acts as an antagonist and nalmefene acts as a partial agonist. Parallel clinical trials for nalmefene or naltrexone have produced widely disparate outcomes and a marked lack of consensus regarding which of the compounds should be used for the treatment of alcohol use disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here we leveraged a mouse model (n\u2009=\u200956 male C57BL\/6\u2009J) to directly compare the efficacy of nalmefene and naltrexone within-subject. After acquiring operant responding for ethanol, each subject underwent four treatment block conditions: nalmefene (0.1\u2009mg\/kg i.p.), naltrexone (1.0\u2009mg\/kg i.p.), the selective kappa opioid receptor agonist U50,488 (1.0\u2009mg\/kg i.p.) and placebo (saline 10\u2009ml\/kg i.p.). Each treatment block consisted of an ethanol self-administration session followed by two subsequent sessions of punished (quinine adulterated) ethanol self-administration sessions with treatment given 30\u2009min prior to each session.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We show that nalmefene and naltrexone have similar efficacy in reducing ethanol consumption, whereas U50,488 increases ethanol consumption. Despite similar effects in aggregate analyses, nalmefene- and naltrexone-induced reductions in drinking are driven by fully separate subpopulations which do not show any beneficial response to the non-preferred compound and display markedly different behavioral phenotypes prior to treatment. A predictive model based on circulating biogenic amines allows for high accuracy classification of nalmefene- versus naltrexone-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Together, these results provide a roadmap for improving alcohol use disorder treatment outcomes via precision application of existing compounds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-025-01369-6","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:07:37Z","timestamp":1768406857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers"],"prefix":"10.1038","volume":"6","author":[{"given":"Zahra Z.","family":"Farahbakhsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-5953","authenticated-orcid":false,"given":"Alex R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne O.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Mukerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-2089","authenticated-orcid":false,"given":"Cody A.","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"1369_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/acer.12669","volume":"39","author":"RZ Litten","year":"2015","unstructured":"Litten, R. Z. et al. Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin. Exp. Res. 39, 579\u2013584 (2015).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (American Psychiatric Association, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1369_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0924-2708.2004.00093.x","volume":"16","author":"F Kiefer","year":"2004","unstructured":"Kiefer, F. et al. Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsychiatr. 16, 233\u2013238 (2004).","journal-title":"Acta Neuropsychiatr."},{"key":"1369_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R","volume":"27","author":"WA Hunt","year":"1971","unstructured":"Hunt, W. A., Barnett, L. W. & Branch, L. G. Relapse rates in addiction programs. J. Clin. Psychol. 27, 455\u2013456 (1971).","journal-title":"J. Clin. Psychol."},{"key":"1369_CR5","unstructured":"Armor, D. J., Polich, J. M. & Stambul, H. B. Alcoholism and Treatment (Rand, 1976)."},{"key":"1369_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2165\/00002512-200219080-00004","volume":"19","author":"C Barrick","year":"2002","unstructured":"Barrick, C. & Connors, G. J. Relapse prevention and maintaining abstinence in older adults with alcohol-use disorders. Drugs Aging 19, 583\u2013594 (2002).","journal-title":"Drugs Aging"},{"key":"1369_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pbb.2012.08.019","volume":"103","author":"JR Ashenhurst","year":"2012","unstructured":"Ashenhurst, J. R., Bujarski, S. & Ray, L. A. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharm. Biochem. Behav. 103, 253\u2013259 (2012).","journal-title":"Pharm. Biochem. Behav."},{"key":"1369_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","volume":"65","author":"RF Anton","year":"2008","unstructured":"Anton, R. F. et al. An evaluation of \u03bc-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch. Gen. Psychiatry 65, 135\u2013144 (2008).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1369_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02442-4","volume":"7","author":"DJ Hinton","year":"2017","unstructured":"Hinton, D. J. et al. Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. Sci. Rep. 7, 2496 (2017).","journal-title":"Sci. Rep."},{"key":"1369_CR10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1111\/acer.14183","volume":"43","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz, K., Roos, C. R., Mann, K. & Kranzler, H. R. Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol. Clin. Exp. Res. 43, 2395\u20132405 (2019).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"1369_CR11","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/adb.12427","volume":"22","author":"CR Roos","year":"2017","unstructured":"Roos, C. R., Mann, K. & Witkiewitz, K. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone. Addiction Biol. 22, 1528\u20131539 (2017).","journal-title":"Addiction Biol."},{"key":"1369_CR12","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","volume":"26","author":"K Mann","year":"2016","unstructured":"Mann, K. et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur. Neuropsychopharmacol. 26, 1941\u20131949 (2016).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1369_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas, D. E. et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311, 1889\u20131900 (2014).","journal-title":"JAMA"},{"key":"1369_CR14","unstructured":"Selincro: Summary of Product Characteristics (Annex 1) (EMA, 2013)."},{"key":"1369_CR15","unstructured":"Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence, Technology Appraisal 325 (NICE, 2014)."},{"key":"1369_CR16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/add.13438","volume":"111","author":"N Fitzgerald","year":"2016","unstructured":"Fitzgerald, N. et al. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction 111, 1477\u20131487 (2016).","journal-title":"Addiction"},{"key":"1369_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W van den Brink","year":"2013","unstructured":"van den Brink, W. et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 48, 570\u2013578 (2013).","journal-title":"Alcohol Alcohol."},{"key":"1369_CR18","doi-asserted-by":"publisher","first-page":"g1531","DOI":"10.1136\/bmj.g1531","volume":"348","author":"D Spence","year":"2014","unstructured":"Spence, D. Bad medicine: nalmefene in alcohol misuse. BMJ 348, g1531 (2014).","journal-title":"BMJ"},{"key":"1369_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S2215-0366(16)30356-X","volume":"3","author":"F Naudet","year":"2016","unstructured":"Naudet, F., Fitzgerald, N. & Braillon, A. Nalmefene for alcohol dependence: a NICE decision. Lancet Psychiatry 3, 1104\u20131105 (2016).","journal-title":"Lancet Psychiatry"},{"key":"1369_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/SAR.S431270","volume":"15","author":"M Green","year":"2024","unstructured":"Green, M., Veltri, C. A. & Grundmann, O. Nalmefene hydrochloride: potential implications for treating alcohol and opioid use disorder. Subst. Abus. Rehabilit. 15, 43\u201357 (2024).","journal-title":"Subst. Abus. Rehabilit."},{"key":"1369_CR21","doi-asserted-by":"publisher","unstructured":"Braillon, A.& Granger, B. Nalmefene and alcohol dependence: a new approach or the same old unacceptable marketing? SAR 75, https:\/\/doi.org\/10.2147\/SAR.S86007 (2015).","DOI":"10.2147\/SAR.S86007"},{"key":"1369_CR22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","volume":"28","author":"DJ Drobes","year":"2004","unstructured":"Drobes, D. J., Anton, R. F., Thomas, S. E. & Voronin, K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin. Exp. Res. 28, 1362\u20131370 (2004).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/sj.npp.1300101","volume":"28","author":"DJ Drobes","year":"2003","unstructured":"Drobes, D. J., Anton, R. F., Thomas, S. E. & Voronin, K. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28, 755\u2013764 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"1369_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/add.13974","volume":"113","author":"C Palpacuer","year":"2018","unstructured":"Palpacuer, C. et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113, 220\u2013237 (2018).","journal-title":"Addiction"},{"key":"1369_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0026-895X(25)09932-8","volume":"45","author":"K Raynor","year":"1994","unstructured":"Raynor, K. et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharm. 45, 330\u2013334 (1994).","journal-title":"Mol. Pharm."},{"key":"1369_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00213-014-3666-3","volume":"232","author":"E Kelly","year":"2015","unstructured":"Kelly, E. et al. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours. Psychopharmacology 232, 305\u2013314 (2015).","journal-title":"Psychopharmacology"},{"key":"1369_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/B978-0-12-381298-8.00022-8","volume":"484","author":"M Connor","year":"2010","unstructured":"Connor, M. & Traynor, J. Constitutively active \u03bc-opioid receptors. Methods Enzymol. 484, 445\u2013469 (2010).","journal-title":"Methods Enzymol."},{"key":"1369_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1124\/jpet.106.118810","volume":"321","author":"D Wang","year":"2007","unstructured":"Wang, D., Sun, X. & Sadee, W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J. Pharm. Exp. Ther. 321, 544\u2013552 (2007).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1369_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/mol.120.119404","volume":"98","author":"ME Barnett","year":"2020","unstructured":"Barnett, M. E., Knapp, B. I. & Bidlack, J. M. Unique pharmacological properties of the kappa opioid receptor signaling through G\u03b1z as shown with bioluminescence resonance energy tranfer. Mol. Pharm. 98, 462\u2013474 (2020).","journal-title":"Mol. Pharm."},{"key":"1369_CR30","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","volume":"30","author":"G Bart","year":"2005","unstructured":"Bart, G. et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity. Neuropsychopharmacology 30, 2254\u20132262 (2005).","journal-title":"Neuropsychopharmacology"},{"key":"1369_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0014-2999(99)00640-8","volume":"383","author":"ER Butelman","year":"1999","unstructured":"Butelman, E. R., Harris, T. J. & Kreek, M. J. Apparent efficacy of \u03ba-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur. J. Pharm. 383, 305\u2013309 (1999).","journal-title":"Eur. J. Pharm."},{"key":"1369_CR32","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","volume":"23","author":"A Gual","year":"2013","unstructured":"Gual, A., He, Y., Torup, L., van den Brink, W., Mann, K. & ESENSE 2 Study Group A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur. Neuropsychopharmacol. 23, 1432\u20131442 (2013).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1369_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000371547","volume":"21","author":"HJ Aubin","year":"2015","unstructured":"Aubin, H. J. et al. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Eur. Addict. Res. 21, 160\u2013168 (2015).","journal-title":"Eur. Addict. Res."},{"key":"1369_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/23808993.2020.1724510","volume":"5","author":"SJ Nieto","year":"2020","unstructured":"Nieto, S. J., Grodin, E. N. & Ray, L. A. On the path toward personalized medicine: implications of pharmacogenetic studies of alcohol use disorder medications. Expert Rev. Precis Med. Drug Dev. 5, 43\u201354 (2020).","journal-title":"Expert Rev. Precis Med. Drug Dev."},{"key":"1369_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.31887\/DCNS.2017.19.3\/gkoob","volume":"19","author":"O George","year":"2017","unstructured":"George, O. & Koob, G. F. Individual differences in the neuropsychopathology of addiction. Dialogues Clin. Neurosci. 19, 217\u2013229 (2017).","journal-title":"Dialogues Clin. Neurosci."},{"key":"1369_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","volume":"17","author":"RZ Litten","year":"2012","unstructured":"Litten, R. Z. et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict. Biol. 17, 513\u2013527 (2012).","journal-title":"Addict. Biol."},{"key":"1369_CR37","doi-asserted-by":"publisher","first-page":"e12903","DOI":"10.1111\/adb.12903","volume":"26","author":"LA Ray","year":"2021","unstructured":"Ray, L. A. et al. The future of translational research on alcohol use disorder. Addict. Biol. 26, e12903 (2021).","journal-title":"Addict. Biol."},{"key":"1369_CR38","first-page":"415","volume":"88","author":"J van der Stel","year":"2015","unstructured":"van der Stel, J. Precision in addiction care: does it make a difference?. Yale J. Biol. Med. 88, 415\u2013422 (2015).","journal-title":"Yale J. Biol. Med."},{"key":"1369_CR39","unstructured":"FDA. FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-prescription-nasal-spray-reverse-opioid-overdose (2023)."},{"key":"1369_CR40","doi-asserted-by":"publisher","first-page":"1110435","DOI":"10.3389\/fpubh.2023.1110435","volume":"11","author":"F Fortinguerra","year":"2023","unstructured":"Fortinguerra, F., Pierantozzi, A. & Trotta, F. The use of medications approved for alcohol use disorders in Italy. Front. Public Health 11, 1110435 (2023).","journal-title":"Front. Public Health"},{"key":"1369_CR41","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1177\/019262339602400620","volume":"24","author":"KP Keenan","year":"1996","unstructured":"Keenan, K. P. et al. The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Toxicol. Pathol. 24, 757\u2013768 (1996).","journal-title":"Toxicol. Pathol."},{"key":"1369_CR42","unstructured":"National Research Council (US) Subcommittee on Laboratory Animal Nutrition. Nutrient Requirements of the Mouse (National Academies Press (US), 1995)."},{"key":"1369_CR43","doi-asserted-by":"crossref","unstructured":"Laman-Maharg, A. et al. Sex differences in the effects of a kappa opioid receptor antagonist in the forced swim test. Front. Pharm. 9, 93 (2018).","DOI":"10.3389\/fphar.2018.00093"},{"key":"1369_CR44","doi-asserted-by":"crossref","unstructured":"Przybysz, K. R., Varlinskaya, E. I. & Diaz, M. R. Age and sex regulate kappa opioid receptor-mediated anxiety-like behavior in rats. Behav. Brain Res. 379, 112379 (2020).","DOI":"10.1016\/j.bbr.2019.112379"},{"key":"1369_CR45","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1124\/molpharm.120.000124","volume":"98","author":"KL Reichard","year":"2020","unstructured":"Reichard, K. L. et al. Regulation of kappa opioid receptor inactivation depends on sex and cellular site of antagonist action. Mol. Pharm. 98, 548\u2013558 (2020).","journal-title":"Mol. Pharm."},{"key":"1369_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbr.2014.01.003","volume":"262","author":"CF Robles","year":"2014","unstructured":"Robles, C. F. et al. Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females. Behav. Brain Res. 262, 84\u201393 (2014).","journal-title":"Behav. Brain Res."},{"key":"1369_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biopsych.2013.07.042","volume":"76","author":"SE Russell","year":"2014","unstructured":"Russell, S. E. et al. Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol. Psychiatry 76, 213\u2013222 (2014).","journal-title":"Biol. Psychiatry"},{"key":"1369_CR48","doi-asserted-by":"crossref","unstructured":"Hartoff, E. H. & Mavrikaki, M. Sex differences in kappa opioid receptor function and their potential impact on addiction. Front. Neurosci. 9, 466 (2015).","DOI":"10.3389\/fnins.2015.00466"},{"key":"1369_CR49","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1038\/s41380-023-01994-4","volume":"28","author":"AR Brown","year":"2023","unstructured":"Brown, A. R. et al. Structured tracking of alcohol reinforcement (STAR) for basic and translational alcohol research. Mol. Psychiatry 28, 1585\u20131598 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1369_CR50","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/sj.npp.1301438","volume":"33","author":"BM Walker","year":"2008","unstructured":"Walker, B. M. & Koob, G. F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33, 643\u2013652 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"1369_CR51","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.lfs.2010.02.013","volume":"86","author":"MD Osborn","year":"2010","unstructured":"Osborn, M. D., Lowery, J. J., Skorput, A. G. J., Giuvelis, D. & Bilsky, E. J. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci. 86, 624\u2013630 (2010).","journal-title":"Life Sci."},{"key":"1369_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejphar.2008.01.004","volume":"583","author":"MF Divin","year":"2008","unstructured":"Divin, M. F., Holden Ko, M. C. & Traynor, J. R. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-na\u00efve and morphine-dependent mice. Eur. J. Pharm. 583, 48\u201355 (2008).","journal-title":"Eur. J. Pharm."},{"key":"1369_CR53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","volume":"319","author":"SA Robinson","year":"2017","unstructured":"Robinson, S. A., Erickson, R. L., Browne, C. A. & Lucki, I. A role for the mu opioid receptor in the antidepressant effects of buprenorphine. Behav. Brain Res. 319, 96\u2013103 (2017).","journal-title":"Behav. Brain Res."},{"key":"1369_CR54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.106.112417","volume":"320","author":"ER Butelman","year":"2007","unstructured":"Butelman, E. R. et al. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J. Pharm. Exp. Ther. 320, 300\u2013306 (2007).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1369_CR55","doi-asserted-by":"publisher","unstructured":"Rose J. H. et al. Supersensitive kappa opioid receptors promotes ethanol withdrawal-related behaviors and reduce dopamine signaling in the nucleus accumbens. Int. J. Neuropsychopharmacol. 19, https:\/\/doi.org\/10.1093\/ijnp\/pyv127 (2016).","DOI":"10.1093\/ijnp\/pyv127"},{"key":"1369_CR56","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1126\/science.aay1186","volume":"366","author":"CA Siciliano","year":"2019","unstructured":"Siciliano, C. A. et al. A cortical-brainstem circuit predicts and governs compulsive alcohol drinking. Science 366, 1008\u20131012 (2019).","journal-title":"Science"},{"key":"1369_CR57","doi-asserted-by":"publisher","first-page":"eabd4074","DOI":"10.1126\/sciadv.abd4074","volume":"7","author":"T Jia","year":"2021","unstructured":"Jia, T. et al. Neural network involving medial orbitofrontal cortex and dorsal periaqueductal gray regulation in human alcohol abuse. Sci. Adv. 7, eabd4074 (2021).","journal-title":"Sci. Adv."},{"key":"1369_CR58","first-page":"126","volume":"6","author":"S Tolomeo","year":"2021","unstructured":"Tolomeo, S., Macfarlane, J. A., Baldacchino, A., Koob, G. F. & Steele, J. D. Alcohol binge drinking: negative and positive valence system abnormalities. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 6, 126\u2013134 (2021).","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"1369_CR59","doi-asserted-by":"publisher","first-page":"102529","DOI":"10.1016\/j.nicl.2020.102529","volume":"29","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y., Constable, R. T., Hien, D., Chung, T. & Potenza, M. N. Brain anatomical covariation patterns linked to binge drinking and age at first full drink. NeuroImage Clin. 29, 102529 (2021).","journal-title":"NeuroImage Clin."},{"key":"1369_CR60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1556\/2006.2022.00006","volume":"11","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Brain structural covariation linked to screen media activity and externalizing behaviors in children. J. Behav. Addict. 11, 417\u2013426 (2022).","journal-title":"J. Behav. Addict."},{"key":"1369_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1556\/2006.2023.00006","volume":"12","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y., Paulus, M. P. & Potenza, M. N. Brain structural co-development is associated with internalizing symptoms two years later in the ABCD cohort. J. Behav. Addict. 12, 80\u201393 (2023).","journal-title":"J. Behav. Addict."},{"key":"1369_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.alcohol.2020.07.004","volume":"88","author":"RR Pulcinelli","year":"2020","unstructured":"Pulcinelli, R. R. et al. Taurine enhances voluntary alcohol intake and promotes anxiolytic-like behaviors in rats. Alcohol 88, 55\u201363 (2020).","journal-title":"Alcohol"},{"key":"1369_CR63","doi-asserted-by":"publisher","first-page":"114892","DOI":"10.1016\/j.bbr.2024.114892","volume":"463","author":"A Miranda-P\u00e1ez","year":"2024","unstructured":"Miranda-P\u00e1ez, A., Marichal-Cancino, B. A., S\u00e1nchez-Castillo, H. & V\u00e1zquez-Le\u00f3n, P. Acute taurine reduced alcohol intake and preference in alcohol-experienced, but not in alcohol-n\u00e4ive rats by central mechanisms. Behav. Brain Res. 463, 114892 (2024).","journal-title":"Behav. Brain Res."},{"key":"1369_CR64","doi-asserted-by":"publisher","first-page":"1032362","DOI":"10.3389\/fnmol.2022.1032362","volume":"15","author":"LB Ferguson","year":"2022","unstructured":"Ferguson, L. B., Mayfield, R. D. & Messing, R. O. RNA biomarkers for alcohol use disorder. Front. Mol. Neurosci. 15, 1032362 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"1369_CR65","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2217\/pgs.12.99","volume":"13","author":"E Setiawan","year":"2012","unstructured":"Setiawan, E., Pihl, R. O., Benkelfat, C. & Leyton, M. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. Pharmacogenomics 13, 1161\u20131172 (2012).","journal-title":"Pharmacogenomics"},{"key":"1369_CR66","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/npp.2012.195","volume":"38","author":"JP Schacht","year":"2013","unstructured":"Schacht, J. P. et al. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology 38, 414\u2013422 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"1369_CR67","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","volume":"28","author":"DW Oslin","year":"2003","unstructured":"Oslin, D. W. et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546\u20131552 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"1369_CR68","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/j.1530-0277.2006.00156.x","volume":"30","author":"JE McGeary","year":"2006","unstructured":"McGeary, J. E. et al. Genetic moderators of naltrexone\u2019s effects on alcohol cue reactivity. Alcohol Clin. Exp. Res. 30, 1288\u20131296 (2006).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR69","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00213-008-1330-5","volume":"201","author":"SG Kim","year":"2009","unstructured":"Kim, S. G. et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 201, 611\u2013618 (2009).","journal-title":"Psychopharmacology"},{"key":"1369_CR70","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1530-0277.2008.00846.x","volume":"33","author":"G Oroszi","year":"2009","unstructured":"Oroszi, G. et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin. Exp. Res. 33, 383\u2013393 (2009).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR71","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1530-0277.2008.00735.x","volume":"32","author":"AJ Arias","year":"2008","unstructured":"Arias, A. J. et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin. Exp. Res. 32, 1159\u20131166 (2008).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR72","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neuropharm.2016.07.022","volume":"110","author":"AN Karkhanis","year":"2016","unstructured":"Karkhanis, A. N., Huggins, K. N., Rose, J. H. & Jones, S. R. Switch from excitatory to inhibitory actions of ethanol on dopamine levels after chronic exposure: role of kappa opioid receptors. Neuropharmacology 110, 190\u2013197 (2016).","journal-title":"Neuropharmacology"},{"key":"1369_CR73","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1523\/JNEUROSCI.4820-14.2015","volume":"35","author":"CA Siciliano","year":"2015","unstructured":"Siciliano, C. A. et al. Voluntary ethanol intake predicts \u03ba-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques. J. Neurosci. 35, 5959\u20135968 (2015).","journal-title":"J. Neurosci."},{"key":"1369_CR74","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1530-0277.2006.00112.x","volume":"30","author":"PW Marinelli","year":"2006","unstructured":"Marinelli, P. W., Lam, M., Bai, L., Quirion, R. & Gianoulakis, C. A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration. Alcohol Clin. Exp. Res. 30, 982\u2013990 (2006).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0169-328X(97)00338-0","volume":"54","author":"AM Mathieu-Kia","year":"1998","unstructured":"Mathieu-Kia, A. M. & Besson, M. J. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Brain Res. Mol. Brain Res. 54, 141\u2013151 (1998).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"1369_CR76","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.alcohol.2016.04.003","volume":"53","author":"CE McGonigle","year":"2016","unstructured":"McGonigle, C. E., Nentwig, T. B., Wilson, D. E., Rhinehart, E. M. & Grisel, J. E. \u0392-endorphin regulates alcohol consumption induced by exercise restriction in female mice. Alcohol 53, 51\u201360 (2016).","journal-title":"Alcohol"},{"key":"1369_CR77","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.3390\/jcm10235696","volume":"10","author":"OV Roschina","year":"2021","unstructured":"Roschina, O. V. et al. Beta-endorphin and oxytocin in patients with alcohol use disorder and comorbid depression. J. Clin. Med. 10, 5696 (2021).","journal-title":"J. Clin. Med."},{"key":"1369_CR78","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1530-0277.1994.tb01452.x","volume":"18","author":"JP de Waele","year":"1994","unstructured":"de Waele, J. P., Kiianmaa, K. & Gianoulakis, C. Spontaneous and ethanol-stimulated in vitro release of beta-endorphin by the hypothalamus of AA and ANA rats. Alcohol Clin. Exp. Res. 18, 1468\u20131473 (1994).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR79","first-page":"1171","volume":"26","author":"X Dai","year":"2002","unstructured":"Dai, X., Thavundayil, J. & Gianoulakis, C. Differences in the responses of the pituitary beta-endorphin and cardiovascular system to ethanol and stress as a function of family history. Alcohol Clin. Exp. Res. 26, 1171\u20131180 (2002).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1369_CR80","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41592-018-0224-7","volume":"15","author":"AH Tuttle","year":"2018","unstructured":"Tuttle, A. H., Philip, V. M., Chesler, E. J. & Mogil, J. S. Comparing phenotypic variation between inbred and outbred mice. Nat. Methods 15, 994\u2013996 (2018).","journal-title":"Nat. Methods"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01369-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01369-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:03:04Z","timestamp":1770814984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01369-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1369"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01369-6","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}